Home > News > Two new issued patents and 12 new patent applications
September 26th, 2004
Two new issued patents and 12 new patent applications
Biophan Technologies, Inc. today announced the filing of 12 new patents in a range of medical applications that further establish the Company’s cutting-edge role in several critical areas of medical science and health care.
Two new issued patents and 12 new patent applications cement Biophan Technologies' leading-edge role in biomedical technology
New Patents Outline Significant Advances in Broad Range of Medical Applications
Rochester, N.Y. September 22, 2004
Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, today announced the filing of 12 new patents in a range of medical applications that further establish the Company’s cutting-edge role in several critical areas of medical science and health care.
The patents, filed by Biophan and its associated companies, Nanoset LLC and Biomed Solutions LLC, outline new advances in the use of Magnetic Resonance Imaging (MRI), as well as nanotechnology coatings, biothermal batteries and opto-electric controls for implanted medical devices.
The two newly issued patents and 12 filed applications expand Biophan's extensive intellectual property portfolio from 80 to a total of 92 issued, pending, owned or licensed patents. The new total includes 21 issued patents and 71 pending, representing a significant strengthening of the Company's prominent leadership position in advanced aspects of biomedical technology.
The new patents and applications involve the following areas:
- Nine of the newly filed patents are related to the Company's 'anti-antenna' geometries for stent designs, enabling the manufacture of stents that do not interfere with MRI imaging of the stent interior – a process critical to diagnosing the healing process and detecting new blockage due to plaque or tissue accumulation. This anti-antenna technology effectively "de-tunes" the stents so they don’t interfere with the radio frequencies used in MRI. The new stent designs can be used independently or in concert with Biophan's previously announced nanomagnetic coatings that improve MRI imaging. The coatings provide an additional method of MRI image compatibility for stents.
- One additional patent applies similar anti-antenna design techniques to medical device leads, catheters and guidewires used in MRI-guided surgery. The new design prevents adverse heating to those devices caused by the MRI radio-frequency fields, and with the previous technologies solves the problems of safety and image compatibility that have impeded the development of MRI interventional medicine.
- Another application extends the firm's technology in nanomagnetic coatings, as well as manufacturing processes used to create and apply them.
- An additional application relates to biothermal power sources used for pacemakers and other implanted devices, expanding Biophan’s coverage to three patents in this area.
In addition, the US Patent office on Sept. 21 issued two previously filed Biophan applications for designs enabling MRI-compatible uses of opto-electronics in pacemakers and other implanted devices.
"These new patents demonstrate both the depth as well as the rapid rate of Biophan’s innovation in a range of areas of biomedical science and health care," said Mr. Weiner. "We are excited about these new milestones in the broadening of our intellectual property portfolio, and about the new opportunities they provide for development and growth of new sources of revenue, and value for our shareholders."
Biophan continues to file patent applications on multiple technologies being developed to solve the complex problems associated with MRI imaging in the presence of implanted devices or surgical tools. The technologies include a range of systems and techniques, including opto-electronics, nanomagnetic coatings, carbon composite coatings, software techniques and specialized device geometries. These can be used individually or in combination.
Other devices benefiting from these techniques include pacemakers, implanted cardioverter defibrillators, drug pumps, neurostimulators and surgical tools.
The performance improvements these technologies provide include reduction or elimination of unwanted tissue and device heating, elimination of unwanted electrical stimulation of nerve tissue, improved MRI imaging of otherwise invisible implants or surgical tools and clear imaging of tissues near or inside these implanted devices.
By eliminating the difficulties and dangers associated with MRI imaging of these devices, Biophan is expanding the uses of MRI as well as bringing its benefits to patients who are currently denied the valuable technology due to safety issues or unusable images.
About Biophan Technologies, Inc.
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA’s Ames Center for Nanotechnology. Biophan’s goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Biophan Technologies, Inc.
Copyright © Biophan Technologies, Inc.
If you have a comment, please
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014
Unraveling the light of fireflies December 17th, 2014
First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014
Atom-thick CCD could capture images: Rice University scientists develop two-dimensional, light-sensitive material December 20th, 2014
Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014
Instant-start computers possible with new breakthrough December 19th, 2014
Aculon Hires New Business Development Director December 19th, 2014
Silicon Valley-Based Foresight Valuation Launches STR-IP™, a New Initiative for Startups to Discover the Value of Their Intellectual Property December 18th, 2014
Chemists Fabricate Novel Rewritable Paper: An attractive alternate to regular paper, UC Riverside-developed technology helps address increasing problems in environment and resource sustainability December 2nd, 2014
Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014
First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014